[{"orgOrder":0,"company":"HypoSpray Pharma","sponsor":"Nascent Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Pritumumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"HypoSpray Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HypoSpray Pharma \/ Nascent Biotech","highestDevelopmentStatusID":"6","companyTruncated":"HypoSpray Pharma \/ Nascent Biotech"}]

Find Clinical Drug Pipeline Developments & Deals by HypoSpray Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO Partnering at JPM
                          Not Confirmed
                          BIO Partnering at JPM
                          Not Confirmed

                          Details : The collaboration aims to develop an alternative delivery mechanism for patients who can benefit from ACA-11 (pritumumab), Nascent's lead monoclonal antibody cancer treatment asset, for Brain Cancer.

                          Brand Name : ACA-11

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 19, 2024

                          Lead Product(s) : Pritumumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Nascent Biotech

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank